AstraZeneca makes $275 million in sales from Covid vaccine

AstraZeneca Covid-19 vaccine

British pharmaceuticals giant AstraZeneca reported on Friday $275 million (227 million euros) in sales from its Covid vaccine in the first three months of the year. It is the first time that the company discloses figures from sales of one of the world's leading vaccines. AstraZeneca's Covid-19 jab was developed with the University of Oxford and has been key in Britain's rapid vaccination drive. The company is selling it at cost price. However, public confidence in the jab has taken a blow over worries of links to very rare blood clots, and the company is in a legal fight with the EU over delivery shortfalls.